LCA10
Putative lung carcinoma-associated protein 10
Also known as: LCA10_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for LCA10 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
164 residues, UniProt reviewed canonical sequence.
>Q71F78|LCA10
1 MSSCPVHDCP SWDPERLEPV ETGSRGALRL RGGAPGSAAG FRASIWGPAG YPSPVGLGHP
61 ASLPRPAYSP RCPEPDARHG WGSGSNAGYR GPDRAGRTPC PAQDREGRSS SPVPPPRLKA
121 MTSQARKQNG GALIDTVDWT REAPDSDPVM SMQKTQKPQT TVGQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LCA10 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.74
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.67
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.2
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LCA10 as an antibody target. Whether an autoantibody or antibody against LCA10 could matter depends on whether native LCA10 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LCA10 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LCA10 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...